Published: Fairfax Media, June 9, 2015
When biotech giant CSL Group conducted a global tender for a $500 million plant to manufacture and supply three new products, Australia threw its hat in the ring. A lack of financial incentives and an uncompetitive tax system were cited as some of the reasons why Australia, which had developed the research and development of the new products to treat haemophilia, later missed out to Switzerland mid last year.
CSL isn’t alone, writes Adele Ferguson.
To read the full story, click here.